NCT05645887撤回2 期
Human Albumin Treatment in Adult Septic Shock. A Study Evaluating Immune Response and Organ Failure.
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 发起方
- Albimmune SL
- 主要终点
- 1.1 Evaluate B cell response to albumin treatment
研究概览
简要总结
The goal of this phase 2, multicenter, randomized, controlled study is to evaluate the effect of albumin treatment on B cell and other immune cell gene exptression in adults with septic shock.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 84 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female ≥ 18 years and <85 years of age.
- •Community-acquired pneumonia, urinary, skin or biliary infection.
- •Treatment with antibiotics at least one course in the first 6 hours of suspected infection.
- •Meets Septic Shock criteria defined by the presence of sepsis with persistent hypotension despite initial adequate volume resuscitation requiring vasopressors for more than 4h to maintain MAP>65 mmHg and having a serum lactate level > 2mmol/L (18mg/L).
- •SOFA score ≥ 5 points.
- •Albumin plasma level <35g/L.
- •Lymphocytes count < 1,100 cel/mL.
- •Admitted to ICU or IMU
排除标准
- •Septic shock lasting for more than 24h.
- •ECMO or hemoadsortion therapy.
- •Contraindications to receive albumin.
- •Nosocomial or healthcare-associated infections (surgical intervention or hospitalization within 30 days prior to diagnosis of sepsis).
- •Chronic Renal Failure (KIDGO stage 3-5) or dialysis.
- •Liver cirrhosis.
- •A known malignancy that is progressing or has required active treatment within the past 3 months.
- •Patient with end-stage disease (unrelated to sepsis) defined as patients who prior to the current hospitalization are expected to live < 6 months (as assessed by the study physician).
- •Known New York Heart Association (NYHA) class II to IV heart failure or unstable angina, acute coronary disease or myocardial infarction within 6 months prior to diagnosis of sepsis.
- •Known immunocompromised state, including human immunodeficiency virus infection, or medication known to be immunosuppressive.
- •Participation in an interventional investigational study within 30 days prior to diagnosis of sepsis.
- •Likely to be non-compliant or uncooperative during the study (e.g. substance abuse, uncontrolled psychiatric disorder or any chronic condition that may interfere with the study).
- •Albumin administration within the last 14 days.
- •Subjects with severe neurological or severe head trauma disorders.
- •Pregnant and/or breast-feeding woman.
- •Patients who cannot provide prior informed consent and when there is documented evidence that the patient has no legal surrogate decision marker and it appears unlikely that the patient will regain consciousness or sufficient ability to provide delayed informed consent.
研究组 & 干预措施
Human Albumim (20%, 300mL, 60gr) in 180 min IV
Experimental
Further doses of albumin (60g/l) will be administered daily from day 0 to day 7 in patients with serum albumin concentrations <35 g/L.
干预措施: Human albumin (Drug)
Saline solution 0,9% (500mL) in 180 min IV
Placebo Comparator
Saline solution will be given from day 0 to day 7.
干预措施: Saline solution (Other)
结局指标
主要结局
1.1 Evaluate B cell response to albumin treatment
时间窗: at day 0
Measured by the Immunology Complex (Discovery Study).
1.3 Evaluate B cell response to albumin treatment
时间窗: at day 3
Measured by the Immunology Complex (Discovery Study).
1.5 Evaluate B cell response to albumin treatment
时间窗: at day 14
Measured by the Immunology Complex (Discovery Study).
1.6 Evaluate other immune cell response to albumin treatment
时间窗: at day 0
Measured by the Immunology Complex (Discovery Study).
1.8 Evaluate other immune cell response to albumin treatment
时间窗: at day 3
Measured by the Immunology Complex (Discovery Study).
1.4 Evaluate B cell response to albumin treatment
时间窗: at day 7
Measured by the Immunology Complex (Discovery Study).
1.7 Evaluate other immune cell response to albumin treatment
时间窗: at day 1
Measured by the Immunology Complex (Discovery Study).
1.9 Evaluate other immune cell response to albumin treatment
时间窗: at day 7
Measured by the Immunology Complex (Discovery Study).
1.10 Evaluate other immune cell response to albumin treatment
时间窗: at day 14
Measured by the Immunology Complex (Discovery Study).
1.2 Evaluate B cell response to albumin treatment
时间窗: at day 1
Measured by the Immunology Complex (Discovery Study).
次要结局
- 1.1. Identify additional biomarkers of the immune response to albumin treatment.(at day 0, 1, 3, 7 and 14.)
- 1.2.1 Evaluate the functionality of antibody-secreting B cells.(at day 0, 1, 3, 7 and 14.)
- 1.2.2 Evaluate the functionality of antibody-secreting B cells.(at day 0, 1, 3, 7 and 14.)
- 1.2.3 Evaluate the functionality of antibody-secreting B cells.(at day 0, 1, 3, 7 and 14.)
- 1.2.4 Evaluate the functionality of antibody-secreting B cells.(at day 0, 1, 3, 7 and 14.)
- 2.1To further investigate the mechanisms of albumin treatment on the immune system.(at day 0, 1, 3, 7 and 14.)
- 5.10 Evaluate the effect of albumin on endothelial and glycocalix function.(at day 0, 1, 3, 7 and 14.)
- 2.2 To further investigate the mechanisms of albumin treatment on the immune system.(at day 0, 1, 3, 7 and 14.)
- 2.3 To further investigate the mechanisms of albumin treatment on the immune system.(at day 0, 1, 3, 7 and 14.)
- 2.4 To further investigate the mechanisms of albumin treatment on the immune system.(at day 0, 1, 3, 7 and 14.)
- 3. Evaluate whether albumin activates B cells at the mucosal interface.(at day 0, 3, 7 and 14.)
- 4.1. Evaluate the effect of albumin treatment on systemic inflammation.(at day 0, 1, 3, 7 and 14.)
- 4.2.1 Evaluate kidney.(at day 0, 1, 3, 7 and 14.)
- 4.2.2 Evaluate kidney.(at day 0, 1, 3, 7 and 14.)
- 4.2.3 Evaluate kidney.(at day 0, 1, 3, 7 and 14.)
- 4.2.4 Evaluate kidney.(at day 0, 1, 3, 7 and 14.)
- 4.2.5 Evaluate kidney.(at day 0, 1, 3, 7 and 14.)
- 4.2.6 Evaluate kidney.(at day 0, 1, 3, 7 and 14.)
- 4.3.1 To explore the effect of albumin on gut mucosa immunoglobulins.(at day 0, 3, 7 and 14.)
- 4.3.2 To explore the effect of albumin on gut mucosa immunoglobulins.(at day 0, 3, 7 and 14.)
- 4.3.3 To explore the effect of albumin on gut mucosa immunoglobulins.(at day 0, 3, 7 and 14.)
- 4.3.4 To explore the effect of albumin on gut mucosa immunoglobulins.(at day 0, 3, 7 and 14.)
- 5.1 Evaluate the effect of albumin on endothelial and glycocalix function.(at day 0, 1, 3, 7 and 14.)
- 5.2 Evaluate the effect of albumin on endothelial and glycocalix function.(at day 0, 1, 3, 7 and 14.)
- 5.3 Evaluate the effect of albumin on endothelial and glycocalix function.(at day 0, 1, 3, 7 and 14.)
- 5.4 Evaluate the effect of albumin on endothelial and glycocalix function.(at day 0, 1, 3, 7 and 14.)
- 5.5 Evaluate the effect of albumin on endothelial and glycocalix function.(at day 0, 1, 3, 7 and 14.)
- 5.6 Evaluate the effect of albumin on endothelial and glycocalix function.(at day 0, 1, 3, 7 and 14.)
- 5.7 Evaluate the effect of albumin on endothelial and glycocalix function.(at day 0, 1, 3, 7 and 14.)
- 5.8 Evaluate the effect of albumin on endothelial and glycocalix function.(at day 0, 1, 3, 7 and 14.)
- 5.9 Evaluate the effect of albumin on endothelial and glycocalix function.(at day 0, 1, 3, 7 and 14.)
- 5.11 Evaluate the effect of albumin on endothelial and glycocalix function.(at day 0, 1, 3, 7 and 14.)
- 5.13 Evaluate the effect of albumin on endothelial and glycocalix function.(at day 0, 1, 3, 7 and 14.)
- 8.1. Proportion of patients dead at 28 and 90 days.(90 days)
- 8.4.2 Evaluate the sequential APACHE II score.(at day 0, 1, 3, 7 and 14.)
- 5.12 Evaluate the effect of albumin on endothelial and glycocalix function.(at day 0, 1, 3, 7 and 14.)
- 6.1 Time on vasopressors.(14 days)
- 6.3 Time on renal replacement.(14 days)
- 8.3. Proportion of re-hospitalized patients at 28 days.(28 days)
- 5.14 Evaluate the effect of albumin on endothelial and glycocalix function.(at day 0, 1, 3, 7 and 14.)
- 8.4.1 Evaluate the sequential SOFA score.(at day 0, 1, 3, 7 and 14.)
- 9. Evaluate quality of life (QoL) at day 90.(At day 0 and 90)
- 10. Proportion of participants with any AEs related to albumin treatment, SAEs and SUSARs.(90 days)
- 6.2 Time on mechanical ventilation.(14 days)
- 7. Proportion of patients with secondary infections.(90 days)
- 8.2. Proportion of patients re-admitted to ICU at 28 days.(28 days)
- 8.4.3 Evaluate the sequential TISS-28 score.(at day 0, 1, 3, 7 and 14.)
研究者
相似试验
招募中
不适用
Study on the Role of Human Serum Albumin in Large Acute Ischemic Stroke of Anterior Circulation After ThrombectomyCerebral IschemiaNCT06629116Tingyu-Yi100
已完成
1 期
Phase Ib of Recombinant Human Albumin InjectionAscitesNCT04701697The First Hospital of Jilin University36
已完成
1 期
Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder CancerNon-muscle Invasive Bladder Cancer (NMIBC)NCT02009332Aadi Bioscience, Inc.21
终止
2 期
A Study in Sepsis Patients With Renal FailureBacterial Infections and MycosesSepsisNCT00511186AM-Pharma36
已完成
2 期
Study of Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion ProteinChemotherapy-induced NeutropeniaNCT02465801Tianjin SinoBiotech Ltd.216